Drugs / QL2302
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07327697 | Dec 2025 → Jul 2026 overdue | — | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL2302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07327697 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07327697 ↗ |